about
CD133 antigen expression in ovarian cancerMiR-200c and HuR in ovarian cancerHerpes simplex virus infection in pregnancySemiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sampleResidual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.Free testosterone drives cancer aggressiveness: evidence from US population studiesLong-term efficacy and safety of human papillomavirus vaccinationSurvival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancerSox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressivenessCells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumorsPaclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking regionLooking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?βIII-Tubulin: biomarker of taxane resistance or drug target?HuR regulates beta-tubulin isotype expression in ovarian cancerProteomic characterization of cytoskeletal and mitochondrial class III beta-tubulinMolecular mechanisms of patupilone resistanceAdrenomedullin in ovarian cancer: foe in vitro and friend in vivo?Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis
P50
Q21093306-EDD4BF2A-1535-44FA-AAE6-9EA6EEE5A51EQ21261258-2E3FF752-C60D-4577-B66E-E2362F11D253Q21296647-8A04D8B0-361A-4F57-9565-F4A05792B0CCQ24797157-E89D564A-2B3C-464C-B182-1C9D2AF03632Q25257587-A575D566-7D47-401E-9DCE-CA145D5F2828Q27324026-0F28FBF8-042D-438B-BF15-36F7415754AAQ28081156-B00EA6E5-82F9-4DE1-A295-F2F58A75C142Q28209016-F83185A8-D2CB-4FB6-9D48-6B5D53416D81Q28236320-23619514-4FB0-4995-8534-CF8EE70577BCQ28236570-4EAAF5D4-235C-4857-B82C-DA5558378BA2Q28247911-A3FC77C6-5314-476F-B3EA-959F39172915Q28254548-98BA17D0-C748-49B4-8D66-94C87A0D40E9Q28263775-22857FEF-3FE3-4C3F-B69D-408E93A307A8Q28265906-D5CF371A-D09A-4CC0-9511-1CCEE8D871ACQ28284878-0E654747-CBE9-419B-BD48-108F61F4C11DQ28286426-C297CFF8-7A82-468A-9B34-3EFF7324DECAQ28288085-684881D1-DE32-47D4-AD3D-1FC67A5D1448Q28303689-D89DBFC9-E7EE-4A16-AB47-4F177A64D9FAQ28481667-10E97738-A460-484A-9842-9E62C0B3B4D6Q28740531-42155340-611B-4314-9AA0-DFCE242503ED
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giovanni Scambia
@ast
Giovanni Scambia
@en
Giovanni Scambia
@es
Giovanni Scambia
@nl
Giovanni Scambia
@sl
type
label
Giovanni Scambia
@ast
Giovanni Scambia
@en
Giovanni Scambia
@es
Giovanni Scambia
@nl
Giovanni Scambia
@sl
prefLabel
Giovanni Scambia
@ast
Giovanni Scambia
@en
Giovanni Scambia
@es
Giovanni Scambia
@nl
Giovanni Scambia
@sl